GET DAILY SIGNALSWhy Is Ginkgo Bioworks (DNA) Stock Up +19.34% Today?
Key Takeaways
- Shares of DNA jumped roughly 19.3%, trading near $13.45 versus a prior close of $11.27.
- The move extends a powerful multi-week rally, coming on top of a 12.5% gain in the previous session tied to a reported collaboration with an Agenus subsidiary.
- Secondary drivers include sustained enthusiasm around the company's AI drug-discovery and autonomous-laboratory partnerships, including its Eli Lilly TuneLab agreement and Google Cloud protein model work.
- Speculative momentum, heavy options activity, and likely short covering are amplifying gains in a high-beta, heavily shorted name.
- Traders are watching upcoming third-quarter earnings, estimated around November 5, as the next major catalyst.
- For more detail on valuation and catalysts, explore Price Targets, Earnings, and Forecast.
- Discover the strongest-performing automated strategies right now by visiting Trending AI Robots.
Opening Summary
Ginkgo Bioworks Holdings, Inc. (DNA), a Boston-based synthetic biology and cell-engineering platform company that is pivoting toward autonomous laboratories and AI-driven drug discovery, extended its recent surge on Wednesday. The stock climbed about 19.3% to roughly $13.45 in afternoon trading, up from a prior closing price of $11.27. The advance marked the second consecutive session of double-digit percentage gains and reflected continued speculative buying in AI-linked biotech names rather than any single new corporate announcement.
Momentum and Short Covering Amplify the Move
The rally in DNA has all the hallmarks of a momentum-driven, technically fueled advance. The shares carry a beta near 1.8, meaning they tend to move sharply in both directions, and they have been a target of heavy options activity in recent weeks. Following a 12.5% gain in the prior session — attributed in part to a reported collaboration agreement with a subsidiary of Agenus — follow-on buying and short covering appear to have pushed the stock through key technical levels, accelerating gains as bullish positioning crowded in.
AI and Autonomous-Lab Partnerships Underpin Sentiment
Beneath the price action, investors have been reacting to a steady stream of partnership announcements that reposition DNA as an AI-and-automation platform for biology. The company's Ginkgo Datapoints business signed an agreement with Eli Lilly's TuneLab, a collaborative AI/machine-learning drug-discovery platform, and it launched a protein large language model built on Google Cloud technology. Ginkgo has also secured roles in high-profile public programs, including providing autonomous-lab access to the National Science Foundation's $1.5 billion X-Labs initiative. These developments have fueled a narrative that the company's laboratory infrastructure and biological datasets are becoming integral to AI-driven drug development, drawing renewed investor interest despite the company's unprofitable operations.
Market Context and Trading Activity
Trading volume has been elevated relative to the company's average daily turnover, consistent with speculative and momentum-driven activity. The move has diverged from the broader healthcare sector, which has traded little changed, underscoring that the rally is stock-specific rather than a reflection of sector-wide strength. The shares have also moved well above their 50-day moving average, a level that has acted as support during the recent rebound from a mid-October slide. Ginkgo remains a volatile, small-cap name, and its price action has frequently outpaced both its sector and the major indices.
What Comes Next for DNA
The next major test for DNA arrives with third-quarter earnings, estimated around November 5. Investors will focus on revenue growth, which has contracted sharply year-over-year following restructuring and the divestiture of the biosecurity business, as well as cash burn and any details on newly announced partnerships. Wall Street sentiment remains cautious, with the consensus rating at Sell or Reduce and an average price target well below the current share price. Risks include persistent operating losses, elevated cash burn, insider selling, and the possibility that momentum reverses as quickly as it built. The terms of the reported collaboration and any concrete revenue contributions from the AI initiatives will be closely scrutinized.
Trending AI Robots
Tickeron offers hundreds of AI-powered trading bots covering thousands of tickers, each built around different strategies, timeframes, performance metrics, and traded symbols. Because market conditions change constantly, only the strongest performers under current conditions are featured in the curated Trending AI Robots section. This makes it a useful starting point for traders looking to monitor which automated strategies are currently generating the most consistent results. Explore the page to see which bots are leading the market today.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
DNA sees its 50-day moving average cross bullishly above its 200-day moving average
The 50-day moving average for DNA moved above the 200-day moving average on October 07, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 62 of 69 cases where DNA's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 90%.
The 10-day moving average for DNA crossed bullishly above the 50-day moving average on September 23, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 16 of 18 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 89%.
Following a +12.81% 3-day Advance, the price is estimated to grow further. Considering data from situations where DNA advanced for three days, in 209 of 248 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
The Aroon Indicator entered an Uptrend today. In 87 of 109 cases where DNA Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 80%.
Bearish Trend Analysis
The 10-day RSI Indicator for DNA moved out of overbought territory on October 06, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 24 similar instances where the indicator moved out of overbought territory. In 22 of the 24 cases, the stock moved lower in the following days. This puts the odds of a move lower at 90%.
The Momentum Indicator moved below the 0 level on October 13, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on DNA as a result. In 76 of 87 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 87%.
The Moving Average Convergence Divergence Histogram (MACD) for DNA turned negative on October 13, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 51 similar instances when the indicator turned negative. In 47 of the 51 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where DNA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
DNA broke above its upper Bollinger Band on October 05, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 42 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.806) is normal, around the industry mean (2.974). P/E Ratio (-2.254) is within average values for comparable stocks, (-0.899). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (135.903) among similar stocks. P/S Ratio (3.397) is also within normal values, averaging (439.237).
The Tickeron Price Growth Rating for this company is 44 (best 1 - 100 worst), indicating steady price growth. DNA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 79 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. DNA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology
Advertisement